ProShare Advisors
TSHA icon

ProShare Advisors’s Taysha Gene Therapies TSHA Stock Holding History

ProShare Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$198K Sell
44,267
-8,196
-16% -$38.1K ﹤0.01% 1587
2025
Q4 		$289K Buy
52,463
+6,424
+14% +$31.2K ﹤0.01% 1482
2025
Q3 		$151K Buy
46,039
+2,293
+5% +$6.49K ﹤0.01% 1766
2025
Q2 		$101K Sell
43,746
-3,449
-7% -$7.49K ﹤0.01% 1876
2025
Q1 		$65.6K Sell
47,195
-11,881
-20% -$19.9K ﹤0.01% 1916
2024
Q4 		$102K Buy
59,076
+14,418
+32% +$29.9K ﹤0.01% 2071
2024
Q3 		$89.8K Buy
44,658
+33,113
+287% +$72.7K ﹤0.01% 1899
2024
Q2 		$25.9K Sell
11,545
-1,558
-12% -$4.53K ﹤0.01% 1795
2024
Q1 		$37.6K Buy
13,103
+1,157
+10% +$2.41K ﹤0.01% 1939
2023
Q4 		$21.1K Buy
+11,946
New +$23.8K ﹤0.01% 1916
2022
Q1 		– Sell
-10,368
Closed -$121K – 2301
2021
Q4 		$121K Buy
+10,368
New +$156K ﹤0.01% 2165

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ProShare Advisors's TSHA Position: Q1 2026 in Review

ProShare Advisors reduced its Taysha Gene Therapies (TSHA) stake by 16% in Q1 2026, selling an estimated $38.1K and leaving 44,267 shares worth $198K. The position accounts for ﹤0.01% of the portfolio, ranked #1587.

ProShare Advisors first reported a position in TSHA in Q4 2021 and has held it in 11 quarters since. The position peaked at $289K in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • ProShare Advisors held 44,267 shares of Taysha Gene Therapies worth $198K as of Q1 2026.
  • ProShare Advisors sold 8,196 Taysha Gene Therapies shares in Q1 2026, an estimated $38.1K.
  • Taysha Gene Therapies made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1587 holding.
  • ProShare Advisors first reported a position in Taysha Gene Therapies in Q4 2021 and has held it in 11 quarters since.
  • ProShare Advisors's Taysha Gene Therapies position peaked at $289K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.